Chun Chen

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 520 citations

Medicine, Pathology, Gefitinib Versus Vinorelbine +8

Integrin-α9 Is Required for Fibronectin Matrix Assembly during Lymphatic Valve Morphogenesis

Eleni Bazigou, Sherry Xie, Chun Chen et al. · Developmental Cell · 2009 · 341 citations · Full text

The α _v β ₁ integrin plays a critical in vivo role in tissue fibrosis

Nilgun Isik Reed, Hyunil Jo, Chun Chen et al. · Science Translational Medicine · 2015 · 293 citations · Full text

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Dongsheng Yue, Shidong Xu, Qun Wang et al. · The Lancet Respiratory Medicine · 2018 · 288 citations

Medicine, Pathology, Erlotinib Versus Vinorelbine +8

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · Journal of Clinical Oncology · 2020 · 261 citations · Full text